Chengdu Olymvax Biopharmaceuticals Inc. A

688319 · SHG · Healthcare / Biotechnology

26.68CNY-0.98 (-3.54%)

Price History

Full chart

Market Stats

Previous Close27.66

Open27.53

Day Range26.60 – 28.09

52-Week Range20.41 – 44.90

Volume3.46M

Market Cap12.64B

P/E (TTM)0.00

Forward P/E0.00

EPS-0.06

Dividend Yield0.00%

Beta0.56

50-Day Avg27.57

200-Day Avg30.15

About

Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b products. The company was founded in 2009 and is based in Chengdu, China.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Shaowen Fan
Employees436
HeadquartersNo. 99 Tianxin Road, Chengdu, China, 611731, China
Websitehttps://www.olymvax.com

Leadership

Mr. Shaowen FanChairman of the Board & GM · b. 1953
Mr. Yong TanCFO & Deputy GM · b. 1974
Ms. Aimin ChenDirector & Deputy GM · b. 1955
Mr. Wei WuSecretary of the Board & Deputy GM · b. 1982
Mr. Xingyao QinAccounting supervisor · b. 1973

Financials

Income Statement

Currency: CNY	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	498.17K	170.18K	419.32K	161.28K	44.65M	76.34M	179.11M	320.11M	487.15M	547.48M	496.12M	588.86M	704.16M
Growth (%)	-	-65.84%	+146.40%	-61.54%	+27586.88%	+70.95%	+134.64%	+78.72%	+52.18%	+12.38%	-9.38%	+18.69%	+19.58%
Cost of Revenue	3.80K	825	2.81K	864	4.35M	11.70M	16.25M	17.84M	28.36M	43.01M	36.73M	29.77M	49.58M
Gross Profit	494.36K	169.35K	416.51K	160.42K	40.30M	64.64M	162.87M	302.27M	458.79M	504.48M	459.39M	559.09M	704.16M
Gross Margin	99.24%	99.52%	99.33%	99.46%	90.26%	84.68%	90.93%	94.43%	94.18%	92.14%	92.60%	94.94%	100.00%
Operating Expense	24.19M	30.68M	56.66M	56.82M	45.59M	85.87M	196.04M	269.14M	357.21M	462.86M	456.29M	537.78M	673.30M
Operating Income	-23.70M	-30.51M	-56.24M	-56.66M	-5.29M	-21.23M	-33.17M	33.13M	101.58M	41.62M	3.10M	21.31M	30.86M
Operating Margin	-4757.02%	-17930.15%	-13412.64%	-35129.41%	-11.84%	-27.81%	-18.52%	10.35%	20.85%	7.60%	0.62%	3.62%	4.38%
EBITDA	-15.66M	-19.68M	-35.89M	-46.31M	10.32M	-9.41M	-15.06M	54.74M	131.59M	74.11M	49.96M	64.78M	59.85M
EBITDA Margin	-3143.47%	-11561.58%	-8558.76%	-28712.92%	23.10%	-12.32%	-8.41%	17.10%	27.01%	13.54%	10.07%	11.00%	8.50%
Net Income	-23.24M	-30.24M	-52.35M	-55.53M	676.13K	-19.01M	-31.04M	36.13M	107.96M	26.58M	17.56M	20.76M	22.23M
Net Income Margin	-4664.27%	-17770.40%	-12485.61%	-34430.80%	1.51%	-24.90%	-17.33%	11.29%	22.16%	4.85%	3.54%	3.53%	3.16%
R&D	-	17.22M	35.56M	39.93M	16.19M	30.62M	44.11M	42.73M	56.36M	121.99M	114.73M	134.23M	132.90M
R&D as % of Total Revenue	-	10115.83%	8480.45%	24760.01%	36.25%	40.11%	24.63%	13.35%	11.57%	22.28%	23.13%	22.80%	18.87%
Interest Expense	3.00M	3.33M	-	-	97.03K	400.26K	1.07M	982.04K	1.36M	5.16M	7.24M	14.52M	14.64M
Interest Expense % of Total Revenue	602.31%	1956.80%	-	-	0.22%	0.52%	0.60%	0.31%	0.28%	0.94%	1.46%	2.47%	2.08%

Balance Sheet

Currency: CNY	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	228.97M	213.72M	265.41M	203.83M	270.90M	282.37M	488.04M	641.26M	1.21B	1.48B	1.61B	1.81B	2.02B
Total Liabilities	60.92M	70.60M	54.72M	18.47M	57.41M	87.89M	147.20M	264.29M	367.22M	587.02M	681.84M	873.54M	1.12B
Total Equity	168.06M	143.12M	206.87M	180.33M	213.49M	194.48M	340.84M	376.97M	844.66M	881.63M	916.91M	924.68M	903.68M
Cash	22.26M	1.56M	56.95M	3.99M	6.48M	11.46M	95.62M	103.98M	254.37M	269.23M	362.07M	224.16M	246.61M
Total Debt	50.00M	47.00M	-	-	-	20.00M	5.00M	25.00M	38.25M	134.03M	237.61M	274.37M	-
Net Debt	27.74M	45.44M	-56.95M	-3.99M	-6.48M	8.54M	-90.62M	-78.98M	-216.11M	-135.20M	-124.47M	50.21M	107.11M

Cash Flow

Currency: CNY	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-19.29M	-13.51M	-27.04M	-42.56M	-21.50M	-16.70M	-41.77M	21.09M	39.96M	-24.55M	44.00M	-9.73M	105.49M
Investing Cash Flow	-39.89M	-4.54M	-12.83M	-6.35M	-35.31M	2.08M	-28.21M	-48.63M	-255.94M	-56.99M	-78.84M	-223.93M	-
Financing Cash Flow	80.50M	-2.64M	94.44M	-4.05M	59.30M	19.60M	154.13M	18.37M	368.79M	103.38M	129.27M	95.91M	-
Capital Expenditure	39.89M	4.62M	12.83M	6.81M	15.74M	18.11M	29.20M	38.85M	69.71M	200.69M	169.88M	207.32M	98.81M
Free Cash Flow	-59.18M	-18.13M	-39.87M	-49.38M	-37.23M	-34.81M	-70.97M	-17.76M	-29.75M	-225.24M	-125.88M	-217.05M	6.68M
Dividends Paid	3.82M	3.69M	2.72M	-	97.03K	400.26K	494.03K	754.70K	1.03M	4.25M	5.99M	29.68M	14.72M
FCF to OCF	306.73%	134.18%	147.47%	116.01%	173.19%	208.48%	169.91%	-84.21%	-74.43%	917.50%	-286.09%	2230.46%	6.33%
Dividend Paid to FCF	-6.45%	-20.34%	-6.83%	-	-0.26%	-1.15%	-0.70%	-4.25%	-3.46%	-1.89%	-4.76%	-13.67%	220.23%

Earnings

Report Date	Aug 24, 2021	Oct 29, 2021	Feb 22, 2022	Apr 27, 2022	Aug 17, 2022	Oct 28, 2022	Apr 25, 2023
EPS Estimate	-	-	-	-	-	-	-
EPS Actual	0.05	0.11	0.08	-0.02	0.09	0.02	-0.03
Surprise	-	-	-	-	-	-	-
Timing	After-hours	After-hours	After-hours	After-hours	Pre-market	After-hours	Pre-market

Key Statistics & Ratios

Market Cap12.64B

Enterprise Value14.04B

Trailing P/E0.00

Forward P/E0.00

Price / Sales16.64

Price / Book15.82

EPS-0.06

Book Value2.14

Revenue (TTM)759.63M

Gross Profit (TTM)691.31M

EBITDA104.36M

Profit Margin-3.13%

Operating Margin14.62%

Return on Equity-2.68%

Return on Assets2.16%

Shares Outstanding405.41M

Shares Float248.66M

Beta0.56

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Dividends

20241×

0.04Jun 25, 2024